Sapanisertib clinical trials
Also written MLN0128 and TAK-228.
How each study uses sapanisertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sapanisertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
47 studies that test it; most in 2017 (13)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 7 |
| 2017 | 13 |
| 2018 | 6 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 35
National Cancer Institute (NCI) (14) · M.D. Anderson Cancer Center (7) · Millennium Pharmaceuticals, Inc. (6) · Calithera Biosciences, Inc (3) · Faeth Therapeutics (3) · Dana-Farber Cancer Institute (2) · Imperial College London (1) · Avera McKennan Hospital & University Health Center (1)
Often tested with
Tested in the same studies.
Serabelisib (7) · Paclitaxel (5) · Telaglenastat hydrochloride (1) · Adavosertib (1) · Afatinib (1) · Binimetinib (1) · Capivasertib (1) · Copanlisib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test sapanisertib.
- Dec 2026Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)Phase 2 · National Cancer Institute (NCI)
- Dec 2026Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)Phase 2 · National Cancer Institute (NCI)
- Feb 2027Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerPhase 1 · National Cancer Institute (NCI)
- Aug 2027Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE TrialPhase 1/2 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses sapanisertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 47
- Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE TrialRecruitingPhase 1/2National Cancer Institute (NCI)NCT06811116Written as Sapanisertib
- Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast CancerRecruitingPhase 1/2Faeth TherapeuticsNCT07558733Written as Sapanisertib
- Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerRecruitingPhase 2Faeth TherapeuticsNCT06463028Written as Sapanisertib
- Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04250545Written as Sapanisertib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Sapanisertib
- Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02503722Written as Sapanisertib
- Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06390865Written as Sapanisertib
- Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06385496Written as Sapanisertib
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02142803Written as Sapanisertib
- Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 MutationsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03047213Written as Sapanisertib
- Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT04479306Written as Sapanisertib
- Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedPhase 1National Cancer Institute (NCI)NCT02159989Written as Sapanisertib
- A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung CancerTerminatedPhase 2Faeth TherapeuticsNCT05275673Written as sapanisertib
- Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT02484430Written as Sapanisertib
- Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)CompletedPhase 2Imperial College LondonNCT03648489Written as TAK228
- Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid TumorsCompletedPhase 1Avera McKennan Hospital & University Health CenterNCT03154294Written as TAK-228
- Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell CarcinomaCompletedPhase 2Bradley A. McGregor, MDNCT03097328Written as TAK-228
- Sapanisertib Before and After Surgery in Treating Patients With Recurrent GlioblastomaTerminatedPhase 1National Cancer Institute (NCI)NCT02133183Written as Sapanisertib
- A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid CancerCompletedPhase 1/2Dana-Farber Cancer InstituteNCT02244463Written as MLN0128
- Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by SurgeryCompletedPhase 2National Cancer Institute (NCI)NCT02893930Written as Sapanisertib
See all 47 studies that test sapanisertib →
Given beside what is tested · 3 — sapanisertib is usual care or a partner of the new treatment
- Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast CancerCompletedPhase 2Calithera Biosciences, IncNCT02049957Written as Sapanisertib
- A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic MalignanciesCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT02412722Written as Sapanisertib
- A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic MalignanciesCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT02327169Written as MLN0128
Codes
What other systems call sapanisertib · ClinicalTrials.gg INT006065
- MeSH (NLM) C572449sapanisertibOne source NLM
- UNII (FDA) JGH0DF1U03SAPANISERTIBConfirmed FDA, NLM, Wikidata
- RxNorm 2395271One source FDA
- Wikidata Q27078072sapanisertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90548SapanisertibOne source FDA
- DrugBank DB11836One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C572449 | sapanisertib | One source NLM |
| UNII (FDA) | JGH0DF1U03 | SAPANISERTIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2395271 | — | One source FDA |
| Wikidata | Q27078072 | sapanisertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90548 | Sapanisertib | One source FDA |
| DrugBank | DB11836 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.